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Background: Current immunodiagnostic tests for tuberculosis (TB) are based on the
detection of an immune response toward mycobacterial antigens injected into the skin
or following an in-vitro simulation in interferon gamma-release assays. Both tests have
limited sensitivity and are unable to differentiate between tuberculosis infection (LTBI) and
active tuberculosis disease (aTB). To overcome this, the use of novel Mycobacterium
tuberculosis (M. tuberculosis) stage-specific antigens for the diagnosis of LTBI and
aTB has gained interest in recent years. This review summarizes current evidence on
novel antigens used for the immunodiagnosis of tuberculosis and discrimination of
LTBI and aTB. In addition, results on measured biomarkers after stimulation with novel
M. tuberculosis antigens were also reviewed.
Methods: A systematic literature review was performed in Pubmed, EMBASE and web
of science searching articles from 2000 up until December 2017. Only articles reporting
studies in humans using novel antigens were included.
Results: Of 1,533 articles screened 34 were included in the final analysis. A wide range
of novel antigens expressed during different stages and types of LTBI and aTB have been
assessed.M. tuberculosis antigens Rv0081, Rv1733c, Rv1737c, Rv2029c, Rv2031 and
Rv2628, all encoded by the dormancy of survival regulon, were among the most widely
studied antigens and showed the most promising results. These antigens have been
shown to have best potential for differentiating LTBI from aTB. In addition, several studies
have shown that the inclusion of cytokines other than IFN-γ can improve sensitivity.
Conclusion: There is limited evidence that the inclusion of novel antigens as well as the
measurement of other biomarkers than IFN-γ may improve sensitivity and may lead to a
discrimination of LTBI from aTB.
Keywords: interferon gamma-release assay, immune-response, clinical studies, active tuberculosis, latent
tuberculosis, cytokines
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INTRODUCTION
Tuberculosis (TB) was globally one of the top 10 causes of
death in 2016 and more than 10 million new cases are estimated
to occur each year (1). Accurate and early identification of
latent tuberculosis infection (LTBI) has become one of the
key strategies to reduce TB incidence in recent years (1, 2).
This strategy is particularly important in those at risk for
rapid progression from LTBI to active tuberculosis (aTB), which
includes immunocompromised individuals and children (3).
The tuberculin skin test for many decades has been the
standard immunodiagnostic test to detect LTBI, measuring the
local response after intradermal injection of a purified protein
derivative (4, 5). As the tuberculin skin test lacks specificity
due to cross-reactivity with non-tuberculosis mycobacteria and
the widely used vaccine strain Mycobacterium bovis Bacillus
Calmette–Guérin (BCG), an in vitro antigen specific cytokine-
based immuno-diagnostic test was developed in the 1990s (6, 7).
The currently used interferon gamma-release assays include early
secretory antigenic target (ESAT)-6 and culture filtrate protein
(CFP)-10 as stimulatory antigens. Both antigens are located in the
region of difference 1, which is absent in BCG and in most non-
tuberculosis mycobacteria rendering these tests more specific
than the tuberculin skin test (8, 9). Interferon gamma-release
assays have now in many setting replaced the tuberculin skin
test for testing LTBI in adults and have been recommended for
use in both resource-rich and resource-limited countries (10).
Interferon gamma-release assays have two major limitations:
limited sensitivity in children, particularly in those under 5 years
of age, and inability to discriminate between LTBI and aTB
(11–13).
Numerous studies have therefore aimed to identify other
proteins from Mycobacterium tuberculosis (M. tuberculosis)
different from ESAT-6 and CFP-10 as potential candidates for
inclusion in immunodiagnostic tests for TB. Several strategies
employing in vitro, in vivo, and in silico approaches have led to the
discovery of novel immunogenic proteins ofM. tuberculosis (14–
16). An important milestone and the basis for these discoveries
was the sequencing of the entire genome of M. tuberculosis
in the late 90ies (17). To summarize the current state of
research, we performed a systematic literature review on studies
in humans that have included novel M. tuberculosis antigens
for immunodiagnostic tests. The aim of this review was to
compare current evidence on novel M. tuberculosis antigens for
the diagnosis of LTBI and aTB and to identify antigens that are
most promising to be included in further research. In addition,
results on measured biomarkers after stimulation with novel
M. tuberculosis antigens were also reviewed.
Abbreviations: CFP-10, 10 kDa culture filtrate protein; DosR, dormancy of
survival regulon; ELISA, enzyme-linked immunosorbent assay; ELISPOT, enzyme-
linked immuno-spot assay; EPTB, extrapulmonary tuberculosis; ESAT-6, 6
kDa early secretory antigenic target; FCM, flow cytometry; HBHA, Heparin-
binding haemagglutinin; LTBI, latent tuberculosis infection; M. tuberculosis,
mycobacterium tuberculosis; PBMC, peripheral blood mononuclear cell; QFT-GIT,
quantiferon tuberculosis gold in tube; Rpf, resuscitation promoting factor; Rv,
rough morphology virulent; TB, tuberculosis.
METHODS
Search Strategy
A systematic literature search was performed guided by preferred
reporting items for systematic reviews and meta-analyses (see
PRISMA checklist Supplementary File 1). Studies measuring the
immune response induced by novel M. tuberculosis antigens in
patients with LTBI and aTB were included. PubMed, Embase
and Web of Science (core collection) were searched for studies
published between Jan 1st 2000 and Dec 31st 2017. Studies
published before 2000 were excluded since interferon gamma-
release assays have been marketed in the late 1990s. The PubMed
search was done using medical subject heading terms. Search
strings were generated for (i) tuberculosis, (ii) antigens, (iii) assay
read-out and (iv) humans. Additional filters were included in the
Embase and Web of science search (see Supplementary File 2
for details on search strategy). Articles in English, French
or German were considered for inclusion. Additional studies
were identified through references of publications identified for
inclusion.
Inclusion and Exclusion Criteria
After initial screening (Figure 1) studies were evaluated
for inclusion based on the following criteria (see also
Supplementary File 3): (i) including patients with LTBI
and/or aTB with details specified on classification of included
patients comprising results from sputum microscopy, culture,
polymerase chain reaction testing, radiography, and standard
immunodiagnostic tests (interferon gamma-release assays or
tuberculin skin test); (ii) further details of the study population
available including age, gender, treatment, and testing for human
immunodeficiency virus, (iii) immune response analyzed in
blood samples for at least one novel antigen not currently or
previously used in commercially available interferon gamma-
release assays or tuberculin skin test (i.e. antigen other than
ESAT-6, CFP-10, Tb7.7, purified protein derivative). If human
immunodeficiency virus positive individuals were included,
separate analysis of results from this patient group was required
for inclusion. For pediatric studies, authors were contacted, if
human immunodeficiency virus status was not specified in the
original publication. Pediatric studies were included if children
were human immunodeficiency virus negative or if human
immunodeficiency virus was highly unlikely based on national
prevalence of the study population. Studies including patients
that have been treated with anti-tuberculous medication for 4
weeks or longer prior to testing were excluded from analysis. The
search and selection of included studies was done by two authors
(NM and NR). In unclear cases a shared decision for inclusion of
the study was made.
Data Extraction and Classification
Data was extracted using a standardized form including the
following variables: First author, year of publication; country;
study population characteristics including age, patient group;
details about methods used including cell type, incubation
duration, type of antigen, assays used for read-out and main
results. According to function, expression and location on
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FIGURE 1 | Selection of articles included in the review.
the genome antigens were grouped into latency associated,
reactivation- and resuscitation- associated or other.
RESULTS
Included Studies
A total of 1,533 records were identified through PubMed, Embase
and Web of Science, of which 28 studies were included in the
analysis (Figure 1). An additional six records were identified
through cross-references of included articles resulting in a final
number of 34 included studies. Reasons for exclusion of studies
are summarized in Supplementary File 4.
Characteristics of Included Studies
Included studies originated from 16 countries with the majority
(12/34, 35%) being from Europe (Table 1). A total of 5,084
patients were included of which 2,325 were classified as LTBI
and 1,252 as aTB. In addition 1,507 healthy controls or other
controls were included. The majority of studies were in adults
only (24/34, 70%;) (18, 20, 21, 23–27, 29–32, 35, 36, 38, 39, 42,
45–51), 8/34 (24%) studies were done in adults and children
(19, 22, 28, 37, 40, 41, 43, 44) and 2/34 (6 %) were done in
children only (33, 34). Outcomes were measured using enzyme-
linked immunosorbent assay (ELISA), enzyme-linked immuno-
spot assay (ELISPOT) and flow cytometry (FCM) in 27, 6 and
12 studies, respectively (Table 1), and some studies used several
different assays for outcome measurement. IFN-γ was measured
as the only outcome in 16/34 (47%) studies. 18/34 (53%) studies
included further cytokines in the analysis most commonly being
IL-2, IL-10, IL-17, and TNF-α (Table 2).
Patient Groups Investigated
Patient groups in the studies included aTB, LTBI, exposed,
healthy, and sick control patients (Tables 1, 3). Criteria for
patients with aTB were similar and mostly consistent across
studies including culture confirmation and/or presence of acid
fast bacilli in sputum smear. Two studies also used positive
polymerase chain reaction results as confirmation of aTB (34, 37).
Further to this in 6/34 (18%) studies diagnosis of aTB was based
on clinical criteria (20, 34, 37, 40, 50, 51). Definitions for LTBI
patients were heterogeneous and highly variable across studies.
Overall 14/34 (41%) studies included a control group of healthy
participants who had negative test results for interferon gamma-
release assays /tuberculin skin test and/or no known history of
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or exposure to aTB (19, 22, 24, 28, 29, 32, 34, 35, 37, 38, 43, 47,
48, 50). A further 2/34 (6%) studies included exposed individuals
into the control group as long as they stayed healthy (e.g., no
symptoms and microbiologically negative or tuberculin skin test
negative) (32, 34). Another 2/34 (6%) studies included a healthy
control group but either no interferon gamma-release assays
/tuberculin skin test was done or the community controls were
tuberculin skin test positive (no exposure) (40, 49). Finally, 1/34
(3%) study included patients with a respiratory disease other than
TB as a control group (18) and 3/34 (9%) included both a healthy
and a sick control group (19, 22, 40). A single patient group was
evaluated by 4/34 (12%) studies being either: active pulmonary
TB (39, 42), pediatric household contacts from TB index cases
(33), or LTBI patients (44).
Types of Antigens Investigated
Over 300 individual novel M. tuberculosis antigens were tested
among the studies included in this review. Table 4 shows a
selection of the most commonly reported 92 antigens that
were reported in these studies. Of those Rv2031c, Rv2029c,
antigens of the Ag85 complex, Rv0475 (HBHA), Rv2628,
Rv1733c, Rv1737c, Rv0081, Rv2032, Rv0867c, and Rv2389c are
among the most frequently tested ones. Most antigens tested
(48 antigens; Rv2031c, Rv2029c, Rv2628, Rv1733c, Rv1737c,
Rv0081, Rv2032) belong to the group of latency associated
antigens. The majority of these 42/48 (88%) are part of the
dormancy of survival regulon (DosR), a region in the genome
comprising approximately 50 genes expressed during latency.
Fewer antigens (e.g., Rv0867c, Rv2389c) belong to the group
of resuscitation associated antigens, which contains 5 different
genes encoding resuscitation promoting factors (Rpfs). Table 5
summarizes the most signicant findings for the most important
antigens assessed in the studies grouped according to family of
antigens.
Latency Associated Antigens
Dormancy of Survival Regulon
Two studies by Chegou et al. and Kassa et al. assessed the immune
response against a wide range of stage-specific antigens, including
serval antigens of the DosR regulon (26, 39). Both studies used
stimulated whole blood to assess IFN-γ response in a long-term
assay. Kassa et al. identified Rv0081, Rv1733c and Rv2006 among
the most immunogenic antigens stimulating high concentrations
of TNF-α, IL-10, and IL-6 in aTB (39). Chegou et al. reported
significant differences in IFN-γ responses for a number of
DosR antigens including Rv1735c, Rv2006, Rv2625c, Rv1996,
Rv2032, Rv2629, Rv3126c, Rv0081, Rv2631, Rv3130c, Rv2624c,
Rv2007c, Rv2028c, and Rv3134 between exposed and aTB (26).
Based on these results a selection of these antigens was tested
in a further study which also measured additional cytokines.
Stimulation with Rv0081, Rv2032, and Rv1737c had the highest
discriminatory potential of aTB vs. exposed when IL-12(p40), IP-
10, IL-10 and TNF-αwere analyzed (27). A study byMensah et al.
evaluated the immune response after stimulation with Rv1733c,
Rv2029c, and Rv2628 to monitor treatment response in aTB
patients (42). Concentrations of several biomarkers including
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TABLE 2 | Summary of cytokines measured in studies included in this review (all cytokines listed).
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IFN-γ, Granzyme B, IL-17, and sIL-2Rα increased during anti-
mycobacterial treatment but only Rv1733c-specific Granzyme B
levels were significantly increased compared to baseline levels.
Hozumi et al. found 6 out of 33 tested DosR antigens (Rv0570,
Rv1996, Rv2004c, Rv2028c, Rv2029c, and Rv3133c) relevant
for differentiation of aTB and LTBI as these induced higher
concentrations of IFN-γ in LTBI (38).
Other DosR antigens such as Rv2031c showed conflicting
results. For example, Belay et al. found that short-term
stimulation with Rv2031c resulted in significantly lower IFN-γ,
TNF-α, and IL-10 concentrations in aTB patients compared to
TB exposed individuals and healthy controls at baseline and over
a 12-month follow-up period (23). Conversely, Goletti et al. and
Hozumi et al. did not find differences in IFN-γ concentrations
upon Rv2031c stimulation in aTB, LTBI patients and controls
(35, 38). Loxton et al. looked at IFN-γ concentrations in 7-
days Rv2031c-stimulated whole blood and found no differences
between aTB and household contacts (41).
Commandeur et al. showed stimulation with Rv1733c,
Rv2029c and Rv2031c resulted in an increase of double and
single cytokine-producing T cells among LTBI patients compared
to healthy controls. Particularly IFN-γ/TNF-α-producing CD8T
cells were the most frequently found subset (29). This supports
findings from a study by Arroyo et al. that reported stimulation
with Rv1737c and Rv2029c increased IFN-γ- and/or TNF-α-
producing CD4 and CD8T cells in patients with LTBI compared
to aTB (21). IFN-γ production in response to Rv2029c was also
significantly increased in LTBI compared to aTB patients and
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TABLE 4 | Summary of antigens used in the studies included in this review.
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Rv2004c • • 2
Rv2006 • • 2
Rv2007c • • • 3
Rv2028c • • • 3
Rv2029c • • • • • • • 7
Rv2030c • 1
Rv2031c • • • • • • • 7
Rv2032 • • • • 4
Rv2034 • 1
Rv2428 • 1
Rv2624c • • 2
Rv2625c • 1
Rv2626c • • 2
Rv2627c • • 2
Rv2628 • • • • • • 6
Rv2629 • • 2
Rv2630 • • 2
Rv2631 • 1
Rv3126c • 1
Rv3127 • 1
Rv3129 • 1
Rv3130c • 1
Rv3131 • 1
Rv3132c • 1
Rv3133c • • 2
Rv3134c • 1
HBHA • • • • • • • • 8
R
e
g
io
n
o
f
d
if
fe
re
n
c
e Rv2659c • • • 3
Rv2660c • • • 3
Rv1284 • • 2
Rv2244 • 1
Rv3353c • 1
(Continued)
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TABLE 4 | Continued
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Rv2958c • 1
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Total 6 1 5 5 3 1 7 1 33 5 6 4 1 1 1 3 1 5 2 1 11 28 1 3 3 3 12 1 2 3 2 1 1 1 164
healthy controls in a study by Bai et al. (22). This study also
included a control group with respiratory disease and showed
that the response to latency antigens Rv2029c, Rv2628, Rv1813c
was negligible in these patients. Araujo et al. used Rv2029c,
Rv2031c and Rv2034 and found an increased IFN-γ response
upon stimulation in the LTBI group; the three antigens combined
were able to detect 95% of LTBI patients (20).
Doddam et al. characterized the immune-response toward
Rv2004c and found that this antigen elicits a strong pro-
inflammatory (TNF-α, IL-8, IL-1β, and IL-12) response in LTBI
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patients compared to aTB and healthy controls (32). Similarly,
Hozumi et al. showed that Rv2004c elicits increased IFN-γ
producing T cells in a population of LTBI patients compared to
aTB and controls in Japan (38).
Response to latency antigens Rv2624-30 were assessed in
several studies. Goletti et al. found stimulation with Rv2628
to result in high concentrations of IFN-γ which the authors
associated with protection against aTB in those patients. Rv2626c
and Rv2627c, however, showed no significant differences in LTBI
vs. aTB patients (35). Araujo et al. and Bai et al. also measured
higher IFN-γ responses in peripheral blood mononuclear cells
stimulated with Rv2628 in LTBI compared to aTB patients and
healthy controls (20, 22). In contrast, results from Peña et al.
suggest Rv2626c, but not Rv2624c and Rv2628 to be a strong
inducers of IFN-γ in LTBI compared to aTB patients and healthy
controls (47). Chegou et al. demonstrated that Rv2624c as well as
Rv2625c induced significantly higher IFN-γ responses in exposed
household contacts compared to aTB patients (26). In a study
by Kassa et al, in aTB patients Rv2627c, Rv2629, and Rv2630
were among the most immunogenic antigens inducing high
concentrations of several cytokines (including TNF-α, IL-6, IL-
10) (39). Bertholet et al. assessed the effect of anti-mycobacterial
treatment in aTB patients and found generally low levels of IFN-
γ in response after treatment initiation. However, Rv2624 was
among the few antigens that showed an increase in stimulated
IFN-γ concentrations over the course of the treatment (24).
Heparin-Binding Hemagglutinin (HBHA,
Rv0475)
A study by Loxton et al. measuring intracellular cytokines
after stimulation with HBHA found IFN-γ/IL-2/IL-17-producing
CD4T cells to be increased in household contacts compared
to aTB. Interestingly, in the same study IFN-γ concentrations
measured in the supernatant of a 7-day stimulation assay using
HBHA did not differ among both groups (41). Similarly, Delogu
et al. tested recombinant methylated HBHA in patients with LTBI
and aTB and found an increased IFN-γ response in patients
with LTBI in both short-term and long-term stimulation assays
(30). Likewise Hougardy et al. were able to show improved
sensitivity compared to ESAT-6 and purified protein derivative
for identification of LTBI in a low-endemic setting using a
4-day stimulation with HBHA (37). Wyndham-Thomas et al.
explored the potential of a 24 h and 96 h stimulation with
HBHA for LTBI diagnosis in a low-TB-endemic setting and
confirmed the diagnostic potential of the shorter incubation in
detecting recent and remote LTBI compared to a commercial
interferon gamma-release assays (50). In another study by
the same authors including human immunodeficiency virus-
infected patients they found a 24 h stimulation with HBHA
induced higher concentrations of IFN-γ compared to 12 other
cytokines measured (51). A further study including human
immunodeficiency virus-infected patients by Delogu et al.
showed that the absence of response toward HBHA correlated
with increased risk of developing aTB indicating that a response
to HBHA may be a correlate for protection (31). Chiacchio et al.
characterized the T cell response toward HBHA among human
immunodeficiency virus-infected and -uninfected patients with
LTBI and aTB and showed IFN-γ production by CD4T cells
to be generally lower in the human immunodeficiency virus-
infected individuals (25). Dreesman et al. reported stimulation
with HBHA in children and found that antigen induced CD4T
cells producing at least one cytokine to be significantly higher
in both LTBI and aTB. Healthy children in that study showed a
negligible cytokine response. In addition they showed that HBHA
induced IL-17-procuding CD4T cells only in young children
below 3 years of age with LTBI but not in aTB patients and older
children, suggesting that age may also influence the performance
of certain antigens (34).
The Starvation Regulon
The starvation regulon are a set of genes upregulated by
M. tuberculosis in response to nutrient deprivation (52). Two
examples that have been tested in a number of studies
included in this review are Rv2659 and Rv2660. In a study by
Govender et al. long-term stimulation of PBMCs with Rv2659
and Rv2660 resulted in an increase of cytokine production
and proportions of IFN-γ/TNF-α/IL-2-producing polyfunctional
CD4T cells in LTBI compared to aTB. However, differences
were more distinct upon stimulation with ESAT-6/CFP-10 and
BCG. No differences were seen for the CD8T cell population
as proliferation and cytokine expression was generally low
(36). Two studies in Greenland looking at remote and recent
LTBI found that stimulation with Rv2659 and Rv2660 resulted
in variable IFN-γ responses over the course of infection and
were not associated with protection against disease progression.
Furthermore, positive responses for those two antigens were
also frequently observed in patients that tested negative in
commercial interferon gamma-release assays, which questions
the reliability of those findings (43, 44).
M. tuberculosis Reactivation-Associated
Antigens and Resuscitation Promoting
Factors
Kassa et al. and Chegou et al. assessed immune responses to
five Rpfs including Rv0867c, Rv1009, Rv1884c, Rv2389c, Rv2450c
(26, 39). Stimulation with all five Rpfs induced significantly
higher IFN-γ responses in household controls compared to aTB
index cases. The two “reactivation-associated antigens” Rv1131
and Rv1471 were frequently recognized in household controls
and showed significant differences resulting in increased INF-
γ production in household contacts compared to aTB (26).
Additional markers and cytokines were explored in a follow-
up study and showed the diagnostic potential of Rv2389c-
specific TGF-α concentrations being the most promising in
discriminating aTB (27). Kassa et al. showed four Rpfs to be the
most immunogenic and found high concentrations of additional
cytokines (e.g., IL-6, IL-10, and TNF-α) in aTB patients (39). A
study in Colombia showed that T cell responses toward Rv2389c
were both mono- or bifunctional with increased frequencies of
IFN-γ and/or TNF-α-producing CD4 and CD8T cells in LTBI
compared to aTB patients (21). Pathakumari et al. were able
to demonstrate the discriminatory potential of Rv0753c specific
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IFN-γ and IFN-γ /TNF-α responses to identify LTBI and aTB
patients (46).
Other M. tuberculosis Antigens
Region of Difference Encoded Antigens
Dosanjh et al. investigated the role of several region of difference
1 encoded antigens in an ELISPOT assay in a study among
children that were household contacts. Rv3873, Rv3878, and
Rv3879c were included as additional antigens to improve
sensitivity of the standard ELISPOT assay. Rv3873 and Rv3878
were found to be predictors of disease progression from LTBI to
aTB (33).
Chen at al. tested a number of region of difference 2- and
region of difference 11-encoded antigens for their potential of
diagnosing LTBI in a BCG-vaccinated population (28). The
immune response toward Rv1978, Rv1980c, Rv1981c, Rv3425,
Rv3429, and Rv1984c was tested in an ELISPOT assay in LTBI
and aTB patients as well as healthy controls. Rv1980c induced the
highest frequency of IFN-γ producing T cells. However, none of
the novel antigens tested did improve sensitivity compared to the
commercial ELISPOT assay. Combining the read-out including
Rv3425, Rv1981c and the region of difference1-encoded antigens
(ESAT-6, CFP-10) however increased sensitivity for detecting
aTB.
Antigens of the Ag85 Complex (Ag85A,
Ag85B, Ag85C)
Antigens of the Ag85 complex (Ag85A, Ag85B, Ag85C) have been
extensively studied and were included in a number of studies
selected in this review. In the newer studies those antigens were
mostly included as “classical” and “reference” antigens (29, 39,
41, 48), however three older studies, recruiting patients in South
America reported more in-depth results (18, 19, 49). Schwander
et al. reported stimulation with Ag85A and Ag85B resulted in
significantly higher IFN-γ producing T cells in both PBMCs
and broncho-alveolar cells of household contacts in a short-term
assay compared to healthy controls (49). Antas et al. measured
the immune response after stimulation with Ag85A and Ag85B
in the course of anti-mycobacterial treatment in aTB patients
and found IFN-γ concentrations to be higher in treated patients
and community controls compared to untreated patients (19).
Alvarez-Corales et al. reported that in addition to IFN-γ also IL-
17 production was increased in exposed non-household contacts
compared to aTB patients when stimulated with Ag85A and
Ag85B (18).
Other Antigens
The secreted protein Rv1860 was found to induce higher
frequencies of polyfunctional T cells dominated by a CD8
immune response in LTBI compared to aTB patients in a study
in India (48).
Alvarez-Corrales explored the potential of several Pro-Pro-
Glu family members in aTB patients and exposed healthcare
workers (18). Rv3347 was a strong inducer of IFN-γ production
in exposed individuals compared to aTB. On the other hand,
IL-17 production was significantly higher in the exposed group
compared to both aTB and healthy controls for the two antigens
Rv0978c and Rv1917c (18).
Li et al. found that the inclusion of Rv3615c as addition in
the commercial ELISPOT test improved sensitivity in detecting
aTB patients. However, specificity was slightly lower compared to
the commercial T-SPOT.TB test and most importantly the study
lacks the inclusion of a LTBI patient group (40).
Pathakumari et al. investigated the role of the secreted proteins
Rv0009 and Rv2204c among LTBI and aTB patients in a long-
term assay. In both studies they looked at several cytokines and
found that IFN-γ and IFN-γ /TNF-α responses to be the most
accurate in identifying LTBI (45, 46).
The secreted antigens Rv0455c, Rv1511, and Rv1626 showed
promise in a study measuring changes in immune response
toward several antigens over treatment course. Bertholet et al.
found that these secreted antigens showed changes in at least
two different cytokines (IFN-γ, TNF-α, or IL-10) in aTB and
associated this with treatment success (24).
DISCUSSION
Our review is, to our knowledge, the first to systematically review
and summarize published evidence on the use of novel antigens
for the diagnosis of TB. Although a large number of studies were
screened for this review, 34 studies only were included in the
final analysis. The main reason leading to the exclusion of many
of the screened studies was the lack of detailed information in
the particular studies relating to study population characteristics
such as age, gender and immune status of the participants. In
addition, clear disease classification for both LTBI and aTB was
commonly missing as well as information whether patients have
been started on treatment before the novel antigens were tested
and what the prior duration of treatment was. Stringent inclusion
criteria were therefore used in this review to enable comparison
between studies and summarize evidence on novel antigens most
promising to improve diagnosis before treatment initiation.
One of the most striking findings is that most of the tested
novel antigens belong to the group of latency associated antigens,
in particular from the DosR regulon. The DosR regulon is
a specific region of the M. tuberculosis genome comprising
approximately 50 genes that are activated during the dormant,
non-replicative state (53). In general, the observed immune
responses induced by these antigens are more pronounced in
patients with LTBI compared to aTB, making these antigens
attractive for distinction of infection vs. disease (54). Further to
their potential for discrimination of LTBI and aTB these antigens
may also be useful for monitoring treatment success in aTB
patients.
The most promising candidate M. tuberculosis DosR regulon
encoded antigens were Rv0081, Rv1733c, Rv1737c, Rv2029c,
Rv2628, which showed high immunogenic potential across
studies and geographical regions (20–22, 26, 27, 29, 35, 38, 39,
42).
Rv0081 is a transcriptional regulator (55) and presumably a
key locus within the DosR regulon under hypoxic conditions
(56). Several studies using long-term incubation in South Africa
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and Ethiopia showed the immunogenic potential of this antigen
(26, 27, 39). However, Kassa et al. only included one group—
being aTB patients—and both studies by Chegou et al. did not
report tuberculin skin test or interferon gamma-release assays
results for the LTBI patient groups. Hozumi et al. showed good
immunogenic potential but addition of Rv0081 in a classic
ELISPOT assay did not result in IFN-γ responses able to
differentiate LTBI vs. aTB (38).
Rv1733c is presumed to be a transmembrane protein and
found to be a highly potent T cell antigen using bioinformatic
analysis by Zvi et al. (15) and Lew et al. (57). Indeed, the
studies in our review show that this antigen elicits a higher
immune response in LTBI patients compared to aTB and healthy
controls. This is in agreement with serval other studies, which
were excluded from the review, that the immune response to
Rv1733c is potentially a good marker for LTBI patients (54, 58–
60). However, only the study of Serra-Vidal et al. was able to
show the discriminatory potential of Rv1733c both in short- and
long-term stimulation assays (60).
Rv1737c is a possible nitrate transporter (61). Four studies in
this review assessed its immunogenicity in long-term stimulation
assays showing increased response in LTBI (21, 26, 27) but
not aTB patients (39). An elevated immune response in LTBI
patients was also described in further studies excluded from the
review (62, 63) including in two studies investigating exposed
individuals across several African sites (58, 64).
Rv2029c is thought to be a phosphofructokinase involved
in glycolysis (65) and has been tested in mice as potential
vaccine candidate antigen (66). It was one of the most widely
used antigens among the studies in our review and the only
antigen with concordant results across studies in short- and long-
term assays. This is in agreement with several other studies not
included in the review (54, 62–64).
Rv2628 was amongst the top ranking 45 antigens from a
list of 189 antigens by Zvi et al. (15). However, its function
is not yet clear (57). Many studies in this review employing a
variety of different assays showed increased immune responses
in LTBI compared to aTB patients (20, 22, 35, 42). Results from
other studies not included in this review further highlight the
importance of this antigen (54, 62, 63).
A further antigen from the DosR regulon is Rv2031c,
also called α-crystallin or heat shock protein X, which has
been described as crucial for growth of M. tuberculosis inside
macrophages during latency (67, 68). Studies in mice and
macrophage models have demonstrated its role during M.
tuberculosis infection (67, 69, 70). The findings of the human
studies included in our review are less clear with some
studies reporting significantly higher cytokine production in
exposed individuals and LTBI compared to aTB patients and
controls.
Beyond the DosR regulon HBHA was a further latency
associated antigen included in several studies for diagnosis of
LTBI. HBHA is a protein that mediates dissemination of TB
through its binding to epithelial cells at the site of primary
infection, a process believed to be key for developing latency
(71, 72). Concentrations of cytokines were significantly higher
in LTBI compared to aTB patients in a number of studies (25,
30, 31, 34, 37, 41, 50, 51). Further to this a few studies including
human immunodeficiency virus-infected individuals showed low
or absent response toHBHAwhichmay correlate with the risk for
disease progression (25, 31). Interestingly in a study not included
in this review HBHA-induced IFN-γ was detectable at the site of
infection of TB disease in the absence of a response in the blood,
suggesting that novel antigens might also be useful as stimulating
antigens in samples from other body sites. As seen for several
other antigens the HBHA-specific cytokine readout likely plays
an important role as shown in a study by Molicotti et al. in which
the ratio of IFN-γ and TNF-α was able to distinguish LTBI from
aTB patients (73).
Further to the latency associated antigens a smaller number
of studies evaluated Rpfs for in-vitro stimulation. Rpfs are a
group of proteins involved in the reactivation of non-growing
mycobacteria. The proteins are attached to theM. tuberculosis cell
wall or secreted rendering them an optimal target for the immune
system (74). The studies included in our review suggest that
the immune response toward Rv0867c and Rv2389c are potent
discriminators of disease stages. Reactivation is a key topic in
TB research and therefore the number of studies investigating
these antigens included in this review is surprisingly low. It is
important to note that a few further studies investigating these
antigens were not included as they did not fulfill the inclusion
criteria. Results from the non-included studies showed similar
results with Rv2389c (60, 63, 75, 76) and Rv0867c (63, 64, 75, 76)
being identified as potent inducers of IFN-γ responses in LTBI
compared to aTB patients and healthy controls.
Many studies report results using antigens from the Ag85
complex (Ag85A, Ag85B, Ag85C) with consistently elevated
cytokine responses in LTBI compared to aTB. The Ag85
complex consists of three secreted proteins that are associated
with virulence and crucial for survival of M. tuberculosis
in macrophages (77). Due to its immune-dominant ability
Ag85 has gained interest in vaccine research in recent years.
There are currently vaccine candidates in clinical research
mostly combining the existing BCG vaccine and additionally
overexpressing a protein of the Ag85 complex (78). If successful
as vaccines, the inclusion of one of these proteins in a novel
diagnostic test could therefore interfere with the diagnosis as a
result of cross-reactivity in a vaccinated population.
Apart from the inclusion of novel antigens, many studies
extend the measurement of cytokines beyond IFN-γ to improve
diagnostic assays (79, 80). Approximately half of the studies
included in this review measured additional cytokines with IL-
2, IL-10, IL-17, and TNF-α being among the most frequently
used ones that improved diagnostic potential. A recent study
by Coppola et al, not reviewed here, provided evidence that
almost half of the new M. tuberculosis antigens tested in LTBI
populations did trigger many other cytokines than IFN-γ, and
often no IFN-γ itself (16).
One limitation of our review is that despite stringent inclusion
criteria, there is inevitable variability between studies particularly
for the patients included in the study groups. Whereas, the
definitions for aTB patients were mostly consistent, there is
considerable heterogeneity in the definition of LTBI patients.
This often resulted from local routine practice of standard
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LTBI diagnosis. One further limitation is that some of the
antigens have already been tested extensively and information on
function and location are available. For others this information
is still unknown, which renders interpretation of study results
speculative in some instances.
CONCLUSIONS
In our review compiling the latest research from novel
M. tuberculosis antigens several studies clearly showed the
discriminatory potential of LTBI from aTB of a number of
antigens with the most promising being latency associated
antigens. Findings for these antigens are consistent across
several studies with immune responses detectable in short-
term incubation periods. Moreover, the inclusion of additional
cytokine read-outs complementing IFN-γ results, appears to
increase discriminatory potential of LTBI from aTB. Despite
these considerable advances in recent years especially children
and immune-compromised patients are highly underrepresented
in these studies and further research investigating novel antigens
in these patient groups need to address this issue.
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